Policy & Regulation
Calliditas Therapeutics appoints new CMO
15 November 2019 -

Calliditas Therapeutics AB (STO:CALTX), a speciality pharmaceutical company, announced on Thursday the appointment of Dr Krassimir Mitchev, PhD, as chief medical officer (CMO), effective 1 December 2019.

Currently, Mitchev is head of Medical Affairs at Calliditas, having joined the company in March 2019. He is an MD and PhD certified in internal and pulmonary medicine, with broad and extensive academic and pharmaceutical industry career experience, including at GSK and UCB. Prior to his current position, he was medical head for haemophilia at SOBI.

Mitchev takes over the role from Dr Jens Kristensen, who has decided to step down for personal reasons. According to the company, Dr Kristensen will remain a key member of the medical team of the company.

Dr Kristensen joined Calliditas in 2016 and has been instrumental in the design of the ongoing phase 3 study (NefIgArd) and the overall clinical development of Calliditas' leading compound Nefecon.

Calliditas Therapeutics is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialisation efforts.